Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression

Fig. 5

FOXM1-PROTAC suppresses tumor growth in vivo. A The protocol of FOXM1-PROTAC treatment in vivo. BALB/c nude mice (n = 21) were subcutaneously (S.C.) injected with HepG2 and MDA-MB-231 cells (106 cells/mouse) into the right axilla. When the tumor volumes reached 50–100 mm3, the mice were randomly divided into three group. FIP-1 or FOXM1-PROTAC (20 mg/kg) was injected directly into tumors (caudal vein injection) once a day for 14 days. The size of engrafted tumors was measured at the interval of two days and tumor samples were collected at Day 28 post the injection of cancer cells. B Changes of tumor volume with administration days in mice injecting with HepG2 cells. C Hepatoma tumor picture after 28 days. D Breast tumor picture after 28 days. E Statistical diagram of tumor volume of mice injected with HepG2 cells in experimental group and control group. F Changes of body weight of mice injected with HepG2 cells. G, Immunohistochemistry of Heart, Liver, Spleen, Lung and Kidney Treated by FIP-1 and FOXM1-PROTAC for 14 Days (20 mg/kg). H, Serum ELISA of xenografted mice treated by FIP-1 and FOXM1-PROTACs (20 mg/Kg). I, ELISA of Heart, Liver, Spleen, Lung and Kidney treated by FIP-1 and FOXM1-PROTACs (20 mg/kg)

Back to article page